167 related articles for article (PubMed ID: 29198946)
1. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
2. Chemoembolization as first-line treatment for hepatocellular carcinoma invading segmental portal vein with tumour burden limited to a monosegmental level.
Hwang H; Kim JH; Ko E; Kim JY; Ko HK; Gwon DI; Shin JH; Kim GH; Chu HH
Br J Radiol; 2024 May; 97(1157):1038-1043. PubMed ID: 38445658
[TBL] [Abstract][Full Text] [Related]
3. Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis.
Liang L; Xing H; Zhang H; Zhong J; Li C; Lau WY; Wu M; Shen F; Yang T
HPB (Oxford); 2018 Feb; 20(2):110-119. PubMed ID: 29174493
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Preoperative MRI-derived 3D Quantitative Tumor Arterial Burden in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.
Peng G; Huang XY; Wang YN; Cao XJ; Zhou X
Radiol Imaging Cancer; 2024 May; 6(3):e230167. PubMed ID: 38607280
[TBL] [Abstract][Full Text] [Related]
5. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.
Wang X; Yang Y
Medicine (Baltimore); 2024 May; 103(20):e38174. PubMed ID: 38758900
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Wang L; Lin L; Zhou W
Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
[TBL] [Abstract][Full Text] [Related]
7. Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients.
Kaewdech A; Sripongpun P; Cheewasereechon N; Jandee S; Chamroonkul N; Piratvisuth T
Clin Transl Gastroenterol; 2021 Feb; 12(2):e00310. PubMed ID: 33605612
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the predictive power of circulating tumor cells for the prognosis of transarterial chemoembolization treatment on patients with advanced hepatocellular carcinoma.
Deng J; Chen W; Wu X; Zhou Y; Li J
Medicine (Baltimore); 2021 Jan; 100(1):e24060. PubMed ID: 33429769
[TBL] [Abstract][Full Text] [Related]
9. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).
Kudo M; Finn RS; Morimoto M; Rau KM; Ikeda M; Yen CJ; Galle PR; Llovet JM; Daniele B; Lim HY; McIlwain DW; Yoshikawa R; Nakamura K; Liang K; Wang C; Abada P; Widau RC; Zhu AX
Liver Cancer; 2021 Sep; 10(5):451-460. PubMed ID: 34721507
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease.
Kirstein MM; Voigtländer T; Schweitzer N; Hinrichs JB; Marquardt J; Wörns MA; Kloeckner R; Fründt TW; Ittrich H; Wacker F; Rodt T; Manns MP; Wege H; Weinmann A; Vogel A
United European Gastroenterol J; 2018 Mar; 6(2):238-246. PubMed ID: 29511553
[TBL] [Abstract][Full Text] [Related]
11. Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma.
Kasuga R; Taniki N; Chu PS; Tamura M; Tabuchi T; Yamaguchi A; Hayatsu S; Koizumi J; Ojiro K; Hoshi H; Kaneko F; Morikawa R; Noguchi F; Yamataka K; Usui S; Ebinuma H; Itano O; Hasegawa Y; Abe Y; Kitago M; Inoue M; Nakatsuka S; Jinzaki M; Kitagawa Y; Kanai T; Nakamoto N
Sci Rep; 2024 May; 14(1):10896. PubMed ID: 38740983
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial.
Peng Z; Fan W; Liu Z; Xiao H; Wu J; Tang R; Tu J; Qiao L; Huang F; Xie W; Zhuang W; Guo W; Li S; Hua Y; Shen S; He Q; Li D; Li J; Kuang M
JAMA Surg; 2024 Apr; ():. PubMed ID: 38568599
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy.
Hsu C; Po-Ching-Liang ; Morita S; Hu FC; Cheng AL
Liver Cancer; 2012 Nov; 1(3-4):168-76. PubMed ID: 24159581
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma.
Fukuda K; Okumura T; Abei M; Fukumitsu N; Ishige K; Mizumoto M; Hasegawa N; Numajiri H; Ohnishi K; Ishikawa H; Tsuboi K; Sakurai H; Hyodo I
Cancer Sci; 2017 Mar; 108(3):497-503. PubMed ID: 28012214
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Survival Benefit by Surgical Resection by the Seven-Eleven Criteria in Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinoma beyond the Milan Criteria.
Huang CT; Chu YL; Su TH; Huang SC; Tseng TC; Hsu SJ; Liao SH; Hong CM; Liu CH; Yang HC; Liu CJ; Chen PJ; Kao JH
Liver Cancer; 2023 Dec; 12(6):539-549. PubMed ID: 38476293
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Kikuchi T; Takeuchi Y; Nouso K; Kariyama K; Kuwaki K; Toshimori J; Iwado S; Moriya A; Hagihara H; Takabatake H; Tada T; Yasunaka T; Sakata M; Sue M; Miyake N; Adachi T; Wada N; Onishi H; Shiraha H; Takaki A; Otsuka M
Liver Int; 2024 Jun; 44(6):1456-1463. PubMed ID: 38488749
[TBL] [Abstract][Full Text] [Related]
17. European Multicenter Study on Degradable Starch Microsphere TACE: The Digestible Way to Conquer HCC in Patients with High Tumor Burden.
Ludwig JM; Iezzi R; Theysohn JM; Albrecht T; Posa A; Gross A
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680272
[TBL] [Abstract][Full Text] [Related]
18. Feasibility Study of Computed Tomographic Radiomics Model for the Prediction of Early and Intermediate Stage Hepatocellular Carcinoma Using BCLC Staging.
Dong H; Yang L; Shaofeng D; Lili G
Technol Cancer Res Treat; 2024; 23():15330338241245943. PubMed ID: 38660703
[TBL] [Abstract][Full Text] [Related]
19. Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
Kobayashi S; Fukushima T; Ueno M; Chuma M; Numata K; Tsuruya K; Arase Y; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Uojima H; Hidaka H; Kusano C; Morimoto M; Maeda S
Liver Int; 2024 Jun; 44(6):1343-1350. PubMed ID: 38436529
[TBL] [Abstract][Full Text] [Related]
20. Effective therapeutic management of hepatocellular carcinoma - on the basis of a clinical case.
Omyła-Staszewska J; Deptała A
Contemp Oncol (Pozn); 2012; 16(1):60-3. PubMed ID: 23788857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
